National Institute of Allergy & Infectious Diseases (NIAID) has awarded new contracts under a Broad Agency Announcement (BAA) for Development of Therapeutic Products for Biodefense & Emerging Infectious Diseases.
The BAA focuses on the development of promising lead therapeutic candidates which have broad spectrum therapeutic activity against viruses or bacterial pathogens or can overcome bacterial and viral drug resistance could extend the clinical utility of existing broad spectrum anti-infectives.
The contracts we awarded to:
- VenatoRx Pharmaceuticals, Inc. – $34,953,279 – Inclusive of the Base Requirement and all options
- AbViro LLC – $24,885,924 – Inclusive of the Base Requirement and all options